(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 26.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Avadel Pharmaceuticals's revenue in 2026 is $248,517,000.On average, 12 Wall Street analysts forecast AVDL's revenue for 2026 to be $35,766,753,190, with the lowest AVDL revenue forecast at $33,027,483,765, and the highest AVDL revenue forecast at $38,791,180,074. On average, 10 Wall Street analysts forecast AVDL's revenue for 2027 to be $45,165,230,533, with the lowest AVDL revenue forecast at $37,477,697,943, and the highest AVDL revenue forecast at $64,680,938,267.
In 2028, AVDL is forecast to generate $48,024,617,655 in revenue, with the lowest revenue forecast at $41,827,325,758 and the highest revenue forecast at $55,678,946,980.